MAPK3
Mitogen-activated protein kinase 3
As of the edition of 20 October 2026, MAPK3 (mitogen-activated protein kinase 3, UniProt P27361) has 7 drugs tested at it and 7 companies on the list, 6 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P27361
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 8
- Disease areas
- Cancer; Digestive system; Hormones; Lungs and airways; Skin and connective tissue; Blood and lymph; Heart and blood vessels; Immune system
- Registered trials of its drugs
- 18
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 2 |
| Stopped | 5 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Temuterkib | Stopped | Phase 2 | none listed |
| MK-8353 | Stopped | Phase 1 | none listed |
| Ravoxertinib | Went quiet | Phase 1 | none listed |
| ASN007 | Went quiet | Phase 1 | none listed |
| CC-90003 | Stopped | Phase 1 | none listed |
| KO-947 | Stopped | Phase 1 | none listed |
| Tizaterkib | Stopped | Phase 1 | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 6 |
| Engaged | 1 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route A |
| Merck & Co. | Route A |
| Kura Oncology | Route A |
The other 4 companies at MAPK3
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at MAPK3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.